| A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. (NCT05263180) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2022-07-25 |
| The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (NCT05394818) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-07-21 |
| First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors (NCT05438329) | DualityBio Inc. | 2022-07-19 |
| Study of AGEN1571 in Participants With Advanced Solid Tumors (NCT05377528) | Agenus Inc. | 2022-07-19 |
| First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (NCT05495295) | Phost'In Therapeutics | 2022-07-18 |
| A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (NCT04797468) | Shanghai Henlius Biotech | 2022-07-18 |
| A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T (NCT05468190) | Chongqing Precision Biotech Co., Ltd | 2022-07-17 |
| An Phase I Study of YY001 in Patients with Advanced Solid Tumors (NCT06228846) | Shanghai Yuyao Biotech Co., Ltd. | 2022-07-14 |
| A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) (NCT05487170) | Ranok Therapeutics (Hangzhou) Co., Ltd. | 2022-07-12 |
| A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor (NCT05429398) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2022-06-30 |
| A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. (NCT05878691) | Glenmark Specialty S.A. | 2022-06-28 |
| IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors (NCT05076591) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-06-20 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500) | Bristol-Myers Squibb | 2022-06-09 |
| A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors (NCT05378178) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-06-08 |
| A Study of TFX05-01 in Patients With Advanced Solid Tumors (NCT05434299) | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 2022-06-05 |
| Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors (NCT05367778) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-06-03 |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors (NCT05315167) | Zhuhai Yufan Biotechnologies Co., Ltd | 2022-05-30 |
| Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors (NCT05309512) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2022-05-27 |
| CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer (NCT05251714) | Treadwell Therapeutics, Inc | 2022-05-27 |
| Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours (NCT05255484) | LaNova Medicines Limited | 2022-05-26 |
| A Study of YL201 in Patients With Advanced Solid Tumors (NCT05434234) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2022-05-25 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors (NCT05479812) | Werewolf Therapeutics, Inc. | 2022-05-20 |
| A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer (NCT05275777) | National University Hospital, Singapore | 2022-05-19 |
| A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (NCT05346484) | Imugene Limited | 2022-05-17 |
| CLN-418 Study on Subjects With Advanced Solid Tumors (NCT05306444) | Harbour BioMed US, Inc. | 2022-05-12 |
| Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors (NCT05188664) | LaNova Australia Pty Limited | 2022-05-10 |
| StrataPATH™ (Precision Indications for Approved Therapies) (NCT05097599) | Strata Oncology | 2022-04-29 |
| First in Human Study of T3P-Y058-739 (T3P) (NCT05120596) | T3 Pharmaceuticals AG | 2022-04-26 |
| An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia (NCT05226468) | New Epsilon Innovation Limited | 2022-04-25 |
| A Study of SHR-1802 in Patients With Advanced Solid Tumor (NCT05208177) | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-22 |
| Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations (NCT05300048) | Faeth Therapeutics | 2022-04-22 |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (NCT05363605) | Fusion Pharmaceuticals Inc. | 2022-04-20 |
| Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (NCT05352750) | Sonnet BioTherapeutics | 2022-04-20 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (NCT05293496) | MacroGenics | 2022-04-19 |
| A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001) (NCT05231746) | STCube, Inc. | 2022-04-18 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| A Study of ILB2109 in Patients With Advanced Solid Malignancies (NCT05278546) | Innolake Biopharm | 2022-04-11 |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT05267626) | Aulos Bioscience, Inc. | 2022-04-04 |
| A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. (NCT05320874) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-04-01 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors (NCT05344742) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-04-01 |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (NCT05159700) | Zhuhai Yufan Biotechnologies Co., Ltd | 2022-03-31 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NCT05252390) | Nuvation Bio Inc. | 2022-03-29 |
| A Study in Patients With Advanced Cancers (NCT05320588) | BiOneCure Therapeutics Inc. | 2022-03-25 |
| Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours (NCT05199753) | LaNova Australia Pty Limited | 2022-03-16 |
| A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors (NCT05202561) | The First Affiliated Hospital of Bengbu Medical University | 2022-03-10 |
| A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors (NCT05258266) | Nanjing Zenshine Pharmaceuticals | 2022-03-09 |
| A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors (NCT05781386) | Jiangsu Simcere Biologics Co., Ltd | 2022-03-06 |
| Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (NCT05126433) | Jazz Pharmaceuticals | 2022-03-03 |
| A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. (NCT05598268) | ImmVira Pharma Co. Ltd | 2022-03-01 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors (NCT05082610) | Hummingbird Bioscience | 2022-02-28 |
| A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors (NCT05205408) | The First Affiliated Hospital of Bengbu Medical University | 2022-02-24 |
| A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors (NCT05169697) | Eucure (Beijing) Biopharma Co., Ltd | 2022-02-21 |
| IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 (NCT05805956) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-02-15 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (NCT05103358) | Aadi Bioscience, Inc. | 2022-02-15 |
| Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) (NCT05246111) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-02-15 |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors (NCT05269316) | Impact Therapeutics, Inc. | 2022-02-11 |
| Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (NCT05414136) | Bio-Thera Solutions | 2022-02-10 |
| First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (NCT05156866) | TORL Biotherapeutics, LLC | 2022-02-02 |
| A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (NCT05490043) | Antengene (Hangzhou) Biologics Co., Ltd. | 2022-01-30 |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (NCT05098132) | Synthekine | 2022-01-25 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors (NCT05971862) | Oscotec Inc. | 2022-01-25 |
| A Study of BTX-1188 in Subjects With Advanced Malignancies (NCT05144334) | Biotheryx, Inc. | 2022-01-24 |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (NCT05143970) | Institut Paoli-Calmettes | 2022-01-21 |
| A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors. (NCT06266923) | Shanghai Pharmaceuticals Holding Co., Ltd | 2022-01-20 |
| Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) (NCT05178888) | Mirati Therapeutics Inc. | 2022-01-20 |
| A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 (NCT05341570) | Betta Pharmaceuticals Co., Ltd. | 2022-01-19 |
| A Study of ZL-1211 in Patients With Advanced Solid Tumor (NCT05065710) | Zai Biopharmaceutical (Suzhou) Co., Ltd. | 2022-01-19 |
| A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer (NCT05205421) | The First Affiliated Hospital of Bengbu Medical University | 2022-01-18 |
| A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (NCT05081609) | Ascendis Pharma Oncology Division A/S | 2022-01-11 |
| A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors (NCT05170958) | Nanjing Leads Biolabs Co.,Ltd | 2022-01-06 |
| A Study of HS-20089 in Patients With Advanced Solid Tumors (NCT05263479) | Shanghai Hansoh Biomedical Co., Ltd | 2022-01-05 |
| A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors (NCT05228119) | The Affiliated Hospital of Xuzhou Medical University | 2022-01-04 |
| Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors (NCT05118841) | Nanjing Zenshine Pharmaceuticals | 2022-01-03 |
| Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients (NCT04912687) | Institut Bergonié | 2022-01-01 |
| A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (NCT05420545) | Chongqing Precision Biotech Co., Ltd | 2021-12-31 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer (NCT05226507) | Nuvectis Pharma, Inc. | 2021-12-31 |
| A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor (NCT05148533) | TJ Biopharma Co., Ltd. | 2021-12-30 |
| Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors (NCT05001516) | Turning Point Therapeutics, Inc. | 2021-12-29 |
| Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects (NCT04989829) | Jiangsu HengRui Medicine Co., Ltd. | 2021-12-27 |
| A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors (NCT05271279) | Beijing Boren Hospital | 2021-12-24 |
| First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors (NCT05103046) | 1200 Pharma, LLC | 2021-12-23 |
| A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (NCT05075564) | Elpiscience Biopharma, Ltd. | 2021-12-23 |
| A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors (NCT05148195) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-12-22 |
| A Study of HB0030 Injection in Patients With Advanced Solid Tumors (NCT05706207) | Huabo Biopharm Co., Ltd. | 2021-12-21 |
| Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors (NCT05156203) | Taivex Therapeutics Corporation | 2021-12-19 |
| A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (NCT04986865) | Antengene Biologics Limited | 2021-12-15 |
| A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations (NCT05372120) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-12-15 |
| Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors (NCT05204862) | TiumBio Co., Ltd. | 2021-12-02 |
| ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors (NCT05276609) | Shanghai Hansoh Biomedical Co., Ltd | 2021-11-28 |
| Study of LM-302 in Patients With Advance Solid Tumors (NCT05161390) | LaNova Medicines Zhejiang Co., Ltd. | 2021-11-26 |
| Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor (NCT05146440) | Grupo Espanol de Investigacion en Sarcomas | 2021-11-23 |
| Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers (NCT05109442) | Affimed GmbH | 2021-11-19 |
| First in Human Study of TORL-1-23 in Participants With Advanced Cancer (NCT05103683) | TORL Biotherapeutics, LLC | 2021-11-17 |
| A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation (NCT05119933) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2021-11-09 |
| A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer (NCT04827810) | Fox Chase Cancer Center | 2021-11-05 |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers (NCT05099549) | NKGen Biotech, Inc. | 2021-11-03 |
| A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (NCT05142423) | Akeso | 2021-11-03 |
| Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression (NCT05163041) | BicycleTx Limited | 2021-11-02 |
| RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT05122572) | Wuxi People's Hospital | 2021-11-01 |
| A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (NCT05117476) | Cullinan Therapeutics Inc. | 2021-10-29 |